Selective T Cell Costimulation Blocker [EPC]

2761 reported adverse events

Drugs of this class: BELATACEPT

These side effects are most commonly reported by patients taking drugs of the Selective T Cell Costimulation Blocker [EPC] class:

#	Side effect	Count
0	OFF LABEL USE	199
1	DEATH	173
2	KIDNEY TRANSPLANT REJECTION	172
3	TRANSPLANT REJECTION	133
4	CYTOMEGALOVIRUS INFECTION	90
5	ACUTE KIDNEY INJURY	83
6	INTENTIONAL PRODUCT USE ISSUE	82
7	SEPSIS	78
8	HOSPITALISATION	77
9	PYREXIA	77

See all common reactions for Selective T Cell Costimulation Blocker [EPC]

Drugs of the Selective T Cell Costimulation Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	DIFFUSE MESANGIAL SCLEROSIS	3	0.2143
1	GENE MUTATION IDENTIFICATION TEST NEGATIVE	1	0.1667
2	HERPES SIMPLEX MENINGITIS	8	0.1600
3	CYTOMEGALOVIRUS MYOCARDITIS	2	0.1429
4	PYELONEPHRITIS FUNGAL	5	0.1351
5	EPIGLOTTIC ERYTHEMA	1	0.1111
6	CUTANEOUS BLASTOMYCOSIS	2	0.0952
7	REMOVAL OF RENAL TRANSPLANT	4	0.0952
8	DISSEMINATED BLASTOMYCOSIS	3	0.0938
9	BK POLYOMAVIRUS TEST POSITIVE	4	0.0930

See all enriched reactions for Selective T Cell Costimulation Blocker [EPC]